First Time Loading...

Atossa Therapeutics Inc
NASDAQ:ATOS

Watchlist Manager
Atossa Therapeutics Inc Logo
Atossa Therapeutics Inc
NASDAQ:ATOS
Watchlist
Price: 1.52 USD -0.65%
Updated: May 3, 2024

Atossa Therapeutics Inc
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Atossa Therapeutics Inc
Operating Income Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Atossa Therapeutics Inc
NASDAQ:ATOS
Operating Income
-$31.4m
CAGR 3-Years
-29%
CAGR 5-Years
-22%
CAGR 10-Years
-11%
Abbvie Inc
NYSE:ABBV
Operating Income
$16.6B
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Operating Income
$8.7B
CAGR 3-Years
24%
CAGR 5-Years
1%
CAGR 10-Years
3%
Amgen Inc
NASDAQ:AMGN
Operating Income
$8.2B
CAGR 3-Years
-4%
CAGR 5-Years
-5%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Income
$3.8B
CAGR 3-Years
10%
CAGR 5-Years
42%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Income
$4.2B
CAGR 3-Years
6%
CAGR 5-Years
11%
CAGR 10-Years
19%

See Also

What is Atossa Therapeutics Inc's Operating Income?
Operating Income
-31.4m USD

Based on the financial report for Dec 31, 2023, Atossa Therapeutics Inc's Operating Income amounts to -31.4m USD.

What is Atossa Therapeutics Inc's Operating Income growth rate?
Operating Income CAGR 10Y
-11%

Over the last year, the Operating Income growth was -13%. The average annual Operating Income growth rates for Atossa Therapeutics Inc have been -29% over the past three years , -22% over the past five years , and -11% over the past ten years .